Revance Therapeutics, Inc. (NASDAQ:RVNC) Given Consensus Recommendation of “Hold” by Analysts

Shares of Revance Therapeutics, Inc. (NASDAQ:RVNC) have been given a consensus recommendation of “Hold” by the nine analysts that are presently covering the stock, Marketbeat.com reports. Eight equities research analysts have rated the stock with a hold rating and one has issued a buy rating on the company. The average 1-year target price among analysts that have issued ratings on the stock in the last year is $8.39.

A number of analysts have issued reports on RVNC shares. Barclays reduced their price objective on Revance Therapeutics from $7.00 to $3.00 and set an “equal weight” rating on the stock in a research note on Monday, December 23rd. Needham & Company LLC reaffirmed a “hold” rating on shares of Revance Therapeutics in a research note on Friday, January 17th. Mizuho dropped their target price on Revance Therapeutics from $6.66 to $3.10 and set a “neutral” rating for the company in a report on Tuesday, December 10th. Finally, StockNews.com assumed coverage on Revance Therapeutics in a report on Tuesday. They issued a “hold” rating for the company.

Hedge Funds Weigh In On Revance Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of RVNC. GSA Capital Partners LLP purchased a new position in Revance Therapeutics during the 3rd quarter valued at $108,000. Accredited Investors Inc. purchased a new position in Revance Therapeutics during the 3rd quarter valued at $67,000. LMR Partners LLP purchased a new position in Revance Therapeutics during the 3rd quarter valued at $11,648,000. Alpine Associates Management Inc. purchased a new position in Revance Therapeutics during the 3rd quarter valued at $21,605,000. Finally, Intech Investment Management LLC purchased a new position in Revance Therapeutics during the 3rd quarter valued at $231,000. Hedge funds and other institutional investors own 97.70% of the company’s stock.

Revance Therapeutics Price Performance

NASDAQ:RVNC opened at $3.65 on Monday. Revance Therapeutics has a 1 year low of $2.30 and a 1 year high of $6.65. The stock’s 50 day simple moving average is $3.62 and its two-hundred day simple moving average is $4.26. The company has a market cap of $381.02 million, a price-to-earnings ratio of -1.89 and a beta of 0.90.

Revance Therapeutics Company Profile

Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company’s lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis.